Netscientific Share Discussion Threads

[74tom] 26/6/2020 12:30

Literally poised to break out - just needs another million or so of shares to be bought IMO. Ended about 7m positive buys vs sells yesterday & Acacia had 8.1m to shift. Around flat today. Patience will pay I think.

[baz9707] 26/6/2020 11:27

Message from Stephen Crowe CFO

[baz9707] 25/6/2020 21:45

Edison note with some new figures.

[baz9707] 25/6/2020 18:45

Fully funded
#NSCI No placing, 3.5m cash enough to see them well into 2021
300k Epibone shares
400k CytoVale shares
700k Drawdown facility
Glycotest 20m value
ProAxsis commercial
All funded
$pdsb 💪
M Lawson 30% pushing for shareholder value through sale of assets at the right price and Divi hxxps://t.co/neJqJ5pZcf

[74tom] 25/6/2020 16:33

Big buy at 6.5 moved everything up, however it was NT to sell even £50 at the end. Finishing at the days high bodes very well regardless.

[rk23] 25/6/2020 16:28

Games going on, smaller amounts sell quote 5.25p and larger 5.8pYet price is 6.25 v 6.75Unless its down to last few minutes of trading day.

[74tom] 25/6/2020 15:19

Yep, given how volatile NSCI has been in the past it's well worth being in before they clear - multiple spikes to 10+ in the last year including the most recent monster that hit 23p in April...

[sphere25] 25/6/2020 15:07

I'm certainly watching 74tom. Some of these speculative overhang plays can go nuts - not that I catch them! Ha

BEGO clearly have the sell order and judging by today's volume Acacia must have sold a large amount of their position.

Probably take a speculative punt here just in case there are fireworks when Acacia clear. Be nice to be in a speculative one that goes nuts!

[74tom] 25/6/2020 14:54

Just waiting for that big print from Acacia - then we'll see the rocket...

[baz9707] 25/6/2020 14:25

ProAxsis 50% owned by netscientific, updated website and hiring new staff.
Big revenue increase recently and should be making profits.
POSITIVE

[baz9707] 25/6/2020 14:12

Jus

Has been happening last few days mms aquire shares jump in and out both on bic and ask.

[74tom] 25/6/2020 12:37

NSCI almost always manages a crazy spike - I'd expect no less this time! 9p my guess once the seller clears and momentum is gained, those selling now are leaving prematurely IMO

[sphere25] 25/6/2020 10:47

DDDD looks a fail, dog of a share. All that buying yesterday and it still can't rally - terrible.

Looks like the punters have moved into another Acacia overhang play today here.

[matt123d] 25/6/2020 10:45

Added a few here

[rk23] 22/6/2020 14:12

PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journ...Source: GlobeNewswire Inc.PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced the publication of data generated by the National Cancer Institute (NCI) based on preclinical studies of PDS Biotech's lead clinical program, PDS0101, in combination with two other investigational anti-cancer agents. The article "Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine" by Rumfield et al. was published in the Journal for ImmunoTherapy of Cancer, and provides strong rationale for clinical evaluation of this three-component treatment combination in a recently initiated NCI-led Phase 2 clinical trial. The results of the NCI's preclinical study indicated that PDS0101 generated both human papillomavirus (HPV)-specific T-cells and an associated antitumor response when used as a monotherapy. When PDS0101 was combined with two other development-stage anti-cancer agents, Bintrafusp alfa (M7824) and NHS-IL12, the data suggest the agents worked synergistically to provide enhanced tumor regression and T-cell response as compared to the agents alone. Dr. Frank Bedu-Addo, PDS Biotech's Chief Executive Officer, commented, "The results of this preclinical study highlight the potential of PDS0101, Bintrafusp alfa (M7824) and NHS-IL12 when administered in combination, to improve treatment outcomes in patients with advanced HPV-associated cancers such as anal, cervical, head and neck and vulvar cancers. We look forward to progressing development of this triple therapeutic combination in the upcoming Phase 2 study in patients with HPV-associated cancers."The studies detailed in the Journal for ImmunoTherapy of Cancer were conducted under an existing Cooperative Research and Development Agreement (CRADA) between PDS Biotech and the NCI. The CRADA includes collaborative development work on both PDS0101 and a second development stage compound, PDS0103.

[baz9707] 19/6/2020 15:14

They would only fundraise if they intend to buy something,

[bob1995] 19/6/2020 14:11

Fundraise coming I expect

[baz9707] 19/6/2020 13:25

Still cannot work this out and why its down here.
6.13 to sell plenty
6.2 to buy no size

[baz9707] 19/6/2020 10:36

My theory is JBER who came recently came into level 2 has took a load of shares and are selling them on.
Once they have finished hopefully onwards and up.